Pegcetacoplan (Syfovre) may increase the risk of conversion to which condition?

Pegcetacoplan (Syfovre) is a complement factor inhibitor that has been studied for its effects on age-related macular degeneration (AMD), particularly in the context of managing wet AMD, which is characterized by choroidal neovascularization (CNV). In the case of this treatment, one of the recognized concerns is that while it may help in managing certain aspects of dry AMD, there is evidence suggesting that it might increase the risk of conversion from a non-exudative form of the disease to wet AMD.

This conversion occurs because dry AMD can progress to wet AMD as a result of underlying pathological changes, including the growth of new blood vessels. Pegcetacoplan's mechanism of action, aimed at reducing inflammation and potentially altering the disease process, could inadvertently create an environment that predisposes an individual to the development of CNV. Therefore, the correct assertion is that receiving treatment with Pegcetacoplan may elevate the risk of transitioning from dry to wet AMD, highlighting the importance of monitoring patients closely for any signs of this progression during treatment.

This understanding emphasizes the dynamic and potentially complex relationship between different forms of AMD and underscores why careful management and observation strategies are essential when using new treatment modalities like Pegcetacoplan.